ClinicalTrials.gg
RecruitingNCT07016035Updated Aug 7, 2025

Translation and Validation of the French mPCOSQ (mPCOSQ-F).

An observational study in Polycystic Ovary Syndrome Health-related Quality of Life, sponsored by CHU de Reims. Recruiting at 1 site in France. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-08-07.

Sponsored by CHU de Reims · Observational

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
350
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Polycystic Ovary Syndrome with a site in France — 9 open to participants now, 10 under way, 1 of them phase 3. Polycystic Ovary Syndrome · France.

Started
2025
with 3 others
Observational
8 of 21
3 open now
Registered
14th of 21
by date
Lead sponsor
2 of 21
CHU de Reims

Among the 21 studies in Polycystic Ovary Syndrome with a site in France, this one is one of 4 that started in 2025, is one of 8 observational ones, and was the 14th registered.

Polycystic Ovary Syndrome

959 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.

Browse Polycystic Ovary Syndrome studies →

Open to participants now

9 of the 21 studies in Polycystic Ovary Syndrome with a site in France are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 120 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 106 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Polycystic Ovary Syndrome with a site in France, or all of them as a file.
02

Study summary

This study is a prospective, observational, bicentric study, evaluating the validity and reliability of a French version of the mPCOSQ questionnaire (mPCOSQ-F), used to assess health-related quality of life (HRQOL) in women with polycystic ovary syndrome.

The first stage of the study consisted in translating the questionnaire from English to French.

Patients agreeing to take part in the study will complete the mPCOSQ-F and the SF-36 (generic HRQOL questionnaire). After 1 to 2 weeks, patients will receive the mPCOSQ-F and complete it again.

Read the detailed description

The aim of this study is to assess the validity and reliability of a French version of the mPCOSQ questionnaire (mPCOSQ-F), used to assess health-related quality of life (HRQOL) in women with polycystic ovary syndrome.

Women aged 18 to 45 years with a diagnosis of polycystic ovary syndrome will be included.

The first stage of the study consisted in translating the questionnaire from English to French.

Patients agreeing to take part in the study will complete the mPCOSQ-F and the SF-36 (generic HRQOL questionnaire). After 1 to 2 weeks, patients will receive the mPCOSQ-F and complete it again.

The pre-test phase purpose is to appraise the face validity and feasibility of the questionnaire through phone interviews with the thirty first respondents.

In the final phase, we aimed to evaluate the validity and reliability of the mPCOSQ, and to compare it to the SF-36.

03

Conditions studied

  • Polycystic Ovary Syndrome Health-related Quality of Life

Keywords

  • polycystic ovary syndrome
  • PCOS
  • quality of life
  • health-related quality of life
  • mPCOSQ
  • questionnaire
  • SF-36
  • French
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients were PCOS women recruited from the Reims University Hospital and the Charleville-Mézières Hospital when presenting to endocrinology, gynaecology or reproductive medicine consults.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged 18 to 45
  • Fluent in french
  • Having a diagnosis of PCOS according to the international recommendations published in 2023
  • Willing to participate in the study
  • Affiliated to the french social security system

Exclusion criteria

Exclusion criteria:

  • Diagnosis of adrenal hyperplasia, androgen-producing tumor, Cushing's syndrome, or thyroid disorder
  • Pregnancy or breast-feeding
  • Under legal protection
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
350 participants (estimated)
Patient registry
No

Groups and cohorts

  • Polycystic ovary syndrome

    patients with Polycystic ovary syndrome

    Other: mPCOSQ-F and SF-36

Interventions

  • OthermPCOSQ-F and SF-36

    Questionnaires

06

What researchers measure

Primary outcomes

  1. Content validity of mPCOSQ as determined by the experts group

    Time frame: At 2 years

  2. Feasibility of mPCOSQ

    Time frame: At 2 years

  3. Acceptability of mPCOSQ

    Time frame: At 2 years

  4. Structure validity of mPCOSQ

    Time frame: At 2 years

  5. Reproductibility of mPCOSQ

    Time frame: At 2 years

  6. Reliabilty of mPCOSQ

    Time frame: At 2 years

  7. Total mPCSOQ score

    Time frame: At 15 days

  8. SF-36 scores

    Time frame: At 1 day

  9. Scores in the " weight " domain based on BMI

    Time frame: At 1 day

  10. Scores in the " fertility " domain based on the need for reproductive medicine or parenthood

    Time frame: At 1 day

  11. Scores in the " hirsutism " domain based on the Ferriman-Gallwey score

    Time frame: At 1 day

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for May 2027, 24 months after the start.

Of 71 non-industry observational studies under Polycystic Ovary Syndrome, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 47. This study's planned 24 months is above that.

Counting every sponsor, half of 74 studies reached it within 14 months; a quarter within 6 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2025
First posted
Jun 11, 2025
StartActual
May 12, 2025
Primary completionEst.
May 12, 2027
CompletionEst.
May 12, 2027
Last update
Aug 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07016035
Lead sponsor
CHU de Reims
Responsible party
Sponsor
First posted
Jun 11, 2025
Start date
May 12, 2025
Primary completion
May 12, 2027 (estimated)
Completion
May 12, 2027 (estimated)
Last update
Aug 7, 2025

Study contacts

Sara BARRAUD
Contact
sbarraud@chu-reims.fr
03 10 73 63 82 ext. 0033
Camille TETU
Contact
ctetu@chu-reims.fr

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion